How to Help Your Patients Save Money on Bronchitol: A Provider's Guide to Savings Programs

For CF care teams, the cost of Bronchitol is not just a patient finance problem — it directly affects adherence, therapy initiation timelines, and clinical outcomes. At approximately $3,826 per month without insurance (over $45,000 per year), Bronchitol is among the most expensive inhaled medications in CF management. This guide provides a practical framework for helping your patients navigate the financial landscape and access the savings programs available to them.

Understanding the Bronchitol Cost Landscape

The cost of Bronchitol varies dramatically by payer and patient assistance status:

Cash price (no insurance): Approximately $3,826/month — effectively inaccessible without assistance for most patients

Commercial insurance (with specialty tier): $100–$500+ per month in specialty tier copays, after prior authorization approval

Commercial insurance with Chiesi CareConnect copay assistance: Substantially reduced out-of-pocket costs; specific amounts depend on program terms

Uninsured/underinsured with patient assistance: Eligible patients may receive Bronchitol at little or no cost through the Chiesi CareConnect PAP

Step 1: Obtain Prior Authorization — The First Financial Hurdle

Before any cost savings program is relevant, your patient must have insurance coverage for Bronchitol. That requires prior authorization. A strong initial PA submission dramatically reduces delays and denials. Build your PA documentation around:

Confirmed cystic fibrosis diagnosis with CFTR mutation documentation if available

Documentation that the BTT was performed and passed, with the date and location

Most recent spirometry results showing FEV1 within the payer's required range

For plans with step therapy: documentation of prior use of or medical reason for not using dornase alfa or hypertonic saline

Clinical rationale: why Bronchitol is appropriate for this patient as an add-on to their current CF regimen

If the PA is denied, appeal promptly. Cite the Phase 3 clinical trial data showing statistically significant FEV1 improvement and, for the relevant trial, the 35.4% reduction in pulmonary exacerbations. Chiesi CareConnect provides PA appeal support.

Step 2: Enroll Patients in Chiesi CareConnect

Chiesi CareConnect is the manufacturer's hub for patient support, and your practice should initiate enrollment simultaneously with the PA process — not after. Waiting until after PA approval delays access to cost savings and specialty pharmacy coordination. CareConnect offers:

Copay assistance card: For commercially insured patients — reduces specialty tier copays. Not available for government-insured patients (Medicare, Medicaid, TRICARE).

Patient assistance program (PAP): For uninsured or underinsured patients who meet income criteria — provides free or significantly reduced-cost Bronchitol

Specialty pharmacy coordination: Directs prescriptions to appropriate specialty pharmacy partners in the distribution network

PA appeal support: CareConnect representatives assist with documentation and support throughout the PA process

To enroll a patient, contact Chiesi CareConnect through the Bronchitol website (bronchitol.com) or have your staff initiate enrollment during the prescription workflow.

Step 3: Direct Medicaid and Medicare Patients to Alternative Programs

Manufacturer copay assistance cannot be used with Medicare, Medicaid, or other government programs. For these patients, alternative resources include:

Chiesi CareConnect PAP: If the patient meets income criteria, they may qualify for the patient assistance program regardless of insurance type

CFF Compass (1-844-COMPASS): The Cystic Fibrosis Foundation's free navigator service can identify financial assistance programs for government-insured and uninsured CF patients

NeedyMeds and RxAssist: Patient assistance program directories where staff can search for Bronchitol or mannitol

Medicare Extra Help (Low Income Subsidy): Medicare beneficiaries with low income may qualify for LIS, which substantially reduces specialty tier copays

Step 4: Optimize Your Practice Workflow to Reduce Delays

Cost-related adherence issues often stem from delays in the access process, not from inability to pay. These workflow optimizations reduce delays:

Schedule the BTT and PA initiation in the same visit — begin both on the day you decide to try Bronchitol

Assign a dedicated staff member to manage specialty drug PAs and follow up within 48–72 hours

Send the prescription directly to a specialty pharmacy (not retail) with the PA number included

Enroll the patient in Chiesi CareConnect at time of prescribing, before the prescription is even filled

Using medfinder to Support Your Patients

When patients can't locate a specialty pharmacy that can fill their Bronchitol prescription, medfinder for providers contacts pharmacies on behalf of patients to identify which ones have the medication available — reducing the burden on your staff and your patients.

For the patient-facing version of this savings guide, see: How to Save Money on Bronchitol in 2026: Coupons, Discounts, and Patient Assistance.

Also see: How to Help Your Patients Find Bronchitol In Stock: A Provider's Guide.